Aries Wealth Management Invests $355000 in AstraZeneca plc (AZN)

Several other equities analysts have also recently issued reports on the company. The stock traded within a range of $33.25 and $34.37. The first sale was made at $41.72 but later the stock became weaker, and closed with a gain of 0.99%.

AZN's mean recommendation on Reuter's scale presents no change from 1.6 thirty days ago to 1.6 now, which indicates a buy consensus from the analyst community. Goldman Sachs Group, Inc. Citigroup raised shares of AstraZeneca to a "buy" rating in a research report on Wednesday, October 18th.

ValuEngine upgraded shares of AstraZeneca (NYSE:AZN) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday. Jefferies Group restated a hold rating and issued a GBX 5,100 ($71.51) target price on shares of AstraZeneca in a research note on Thursday, November 16th. Investec raised their price objective on shares of AstraZeneca from GBX 4,900 ($68.70) to GBX 5,500 ($77.12) and gave the stock a "buy" rating in a report on Monday, November 6th. The company now has a consensus rating of Hold and a consensus price target of $35.20. As of today, the company has a SMA200 (200-day simple moving average) of 3.46 Percent. The firm has a market capitalization of $88,710.00, a P/E ratio of 24.50, a PEG ratio of 2.78 and a beta of 0.74. AstraZeneca PLC had 607 analyst reports since July 23, 2015 according to SRatingsIntel. Stock traders bought 8,259 put options on the stock. That compares with the recent volume average of 3.29 million. JP Morgan maintained AstraZeneca PLC (LON:AZN) rating on Tuesday, August 23. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. AstraZeneca had a return on equity of 35.56% and a net margin of 13.36%. AstraZeneca's quarterly revenue was up 3.4% on a year-over-year basis.


EPS Estimate for the next year is 1.69. AstraZeneca has a 52-week low of $27.71 and a 52-week high of $36.70. Stockholders of record on Friday, February 16th will be given a $0.95 dividend. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, February 15th. Astrazeneca PLC's dividend payout ratio (DPR) is now 44.92%. The stock jumped 14.11 percent over the past six months. Dimensional Fund Advisors LP now owns 2,163,183 shares of the company's stock worth $73,743,000 after buying an additional 112,618 shares during the last quarter. Nationwide Fund Advisors increased its holdings in AstraZeneca by 1.7% in the second quarter.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, February 2nd. Primecap Management Co. CA now owns 34,310,950 shares of the company's stock worth $1,068,443,000 after buying an additional 8,330,675 shares in the last quarter. The short interest to Astrazeneca Plc's float is 0.54%. BlackRock Inc. now owns 6,910,657 shares of the company's stock worth $215,198,000 after buying an additional 6,908,257 shares in the last quarter. Quadrant Capital Group LLC grew its position in AstraZeneca by 18.4% in the 2nd quarter. Wellington Management Group LLP now owns 63,250,780 shares of the company's stock worth $1,969,630,000 after buying an additional 4,605,694 shares in the last quarter.

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. Now trading with a market value of 86.85B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. The companyƂ's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Related:

Comments

Latest news

Medical Properties Trust, Inc. (MPW) stock ends Yesterday with change of 1.23%
The stock, as of last close, traded 4.03% away to its 52 week low and was at a distance of -12.91% from its 52 week high. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock.

Plane skids off a runway at BWI; no injuries reported
No injuries were reported, and the passengers were taken off the plane, before going back to the airport terminal. Freezing rain has settled over the Baltimore are, and drivers are seeing icy roads throughout the region.

National Signing Day 2018: Recruiting Class Rankings
Ohio State was Oats' dream school growing up, and Oats told The Athletic that he was indeed a "take" for the Buckeyes. This is a lighter national signing day than usual because the majority of prospects signed in December.

American Express Company (AXP) - Analyst rating score stands at 2.60
Conning Inc decreased its stake in American Express Co (AXP) by 10.28% based on its latest 2017Q3 regulatory filing with the SEC. It is negative, as 57 investors sold PAYX shares while 263 reduced holdings. 67 funds opened positions while 200 raised stakes.

Robert Lewandowski targets Real Madrid transfer this summer
Heynckes has already faced PSG this season, with Bayern facing the French giants in the group stages earlier in the season. If Madrid are to beat PSG over two legs, they are going to need an in-form Ronaldo to influence the contest.

Other news